期刊名称：JOURNAL OF NEUROCHEMISTRY
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
|
The Journal of Neurochemistry is the leading source for current research worldwide on the molecular, chemical, and cellular biology of the nervous system. Each issue contains dozens of full-length presentations of significant original findings, written by investigators at leading medical and research institutions around the world.
The Journal of Neurochemistry is devoted to the prompt publication of high-quality original findings in areas relevant to molecular, chemical, and cell biological aspects of the nervous system. Papers that are wholly pharmalogical, histochemical, or immunological, and methods papers or the cloning of confirmatory sequences that do not advance knowledge in neurochemistry are not normally considered. The Journal particularly encourages submissions in the areas of molecular and cellular biology.
A highlight of each issue is the Journal's critically acclaimed Rapid Communications section, presenting new ideas and data of particular importance and timeliness. The Journal's Mini-Reviews present concise, self-contained summaries of current research in particularly important areas. Print ISSN: 0022-3042
Online ISSN: 1471-4159 |
|
Instructions to Authors
Online submission and a summary of instructions for submission of manuscripts online are available at:
http://jneurochem.manuscriptcentral.com
Final versions of all accepted manuscripts must be supplied both as hard copy and on disk; please refer to section 11 below.
I. GENERAL
1. Journal of Neurochemistry encourages submission online at http://jneurochem.manuscriptcentral.com. Submission online enables rapid review and allows online manuscript tracking. Full instructions and support are available online from the menu to the left of this page and also from the Journal of Neurochemistry submission site.
Please do not duplicate your submission by submitting online and as hard copy. If in doubt, you must contact the appropriate Editorial Office: for the Americas please contact the Editorial Coordinator in Montreal, for the rest of the world, please contact the Editorial Coordinator in Leeds.
2. Journal of Neurochemistry is devoted to the prompt publication of high-quality original findings in areas relevant to molecular, chemical and cell biological aspects of the nervous system. Papers that are wholly pharmacological, histochemical, or immunological, and methods papers or the cloning of confirmatory sequences that do not advance knowledge in neurochemistry will not normally be considered. Although papers in any area of neurochemistry will be considered, the Journal particularly encourages submissions in the areas of molecular and cellular biology. Papers that require extensive revision or further experimentation will be rejected. When revision is invited, such revision must be done within 2 months.
3. Three types of papers are considered: (a) Original Articles (full papers) should be written in the style described in section III. The more concise and well written a paper, the more rapidly it will be processed. (b) Rapid Communications are brief papers that present new ideas and data of particular originality and timeliness. The criteria for acceptance of Rapid Communications will be more stringent than for Original Articles. Rapid Communications must be complete pieces of work and are not intended to provide a means to publish preliminary findings. Decisions on acceptability will be made within one month of receipt and papers will normally be published within three months of acceptance. (c) Reviews and Mini-Reviews usually are invited but unsolicited reviews can be considered and will be subjected to rigorous editorial assessment. It is recommended to send first a synopsis to the Editor for either Reviews or Mini Reviews.
4. Submission of a paper in the Journal of Neurochemistry will be held to imply that it represents original research not previously published (except as an abstract or preliminary report), that it is not being considered for publication elsewhere, and that, if accepted, it will not be published elsewhere in similar form, in any language, without the consent of the International Society for Neurochemistry. Each person listed as an author is expected to have participated in the study to a significant extent, and to have agreed to the content of the manuscript. Although the editors and referees make every effort to ensure the validity of published papers, the final responsibility rests with the authors, not with the Journal, its editors, or publisher.
5. All authors are expected to abide by accepted ethical standards. In investigations that involve human subjects or laboratory animals, authors should provide an explicit statement in Materials and methods/Experimental procedures that the experimental protocols were approved by the appropriate institutional review committee and meet the guidelines of their responsible governmental agency. The steps taken to avoid unjustified procedures and discomfort should be stated. In the case of human subjects informed consent is essential.
6. Publication of descriptions of new recombinant nucleic acid or monoclonal antibody preparations will be on the understanding that the authors are willing to supply samples of such materials in response to reasonable scientific requests.
7. Journal of Neurochemistry is covered by Blackwell Publishing’s OnlineEarly service. OnlineEarly articles are complete full-text articles published online in advance of their publication in a printed issue. Articles are therefore available as soon as they are ready, rather than having to wait for the next scheduled print issue. OnlineEarly articles are complete and final. They have been fully reviewed, revised and edited for publication, and the authors?final corrections have been incorporated. Because they are in final form, no changes can be made after online publication. The nature of OnlineEarly articles means that they do not yet have volume, issue or page numbers, so OnlineEarly articles cannot be cited in the traditional way. They are therefore given a Digital Object Identifier (DOI), which allows the article to be cited and tracked before it is allocated to an issue. After print publication, the DOI remains valid and can continue to be used to cite and access the article. More information about DOIs can be found at: http://www.doi.org/faq.html
II. SUBMISSION OF PAPERS Original Articles, Rapid Communications, Reviews and Mini-Reviews can be submitted online or as hard copy.
For reviewing purposes, the journal prefers to receive a single PDF file containing both the text and the figures.
Manuscript submission online can be in Word document (.doc), Rich Text Format (.rtf), Portable Document Format (.pdf) or PostScript (.ps), provided that the figures are embedded in the text (or at the end of it) and clearly numbered. Each of these file formats will be converted automatically to PDF for reviewing purposes. It is imperative that the author reviews the converted PDF file as it will be seen by the referees.
If necessary, high resolution figures can be embedded in the native word processor file or may be uploaded separately in one of the following formats: GIF, JPEG, TIFF, EPS. Figures uploaded separately in these file formats will be automatically converted to small jpegs for reviewing.
1. If submission on-line is not possible the manuscript may be submitted as hard copy. For hard copy submission of Original Articles, the original plus four copies of any manuscript including five originals of any photographs and a disk containing both text and figure files should be submitted to the appropriate Chief Editor. Papers from Europe, Asia, Africa and Australasia should be submitted to Prof. A. J. Turner, School of Biochemistry and Molecular Biology, University of Leeds, Leeds LS2 9JT, UK, and those from the Americas, to Dr. B. Collier, Department of Pharmacology and Therapeutics, McGill University, McIntyre Medical Sciences Building, Room 1316, 3655 Promenade Sir-William-Osler, Montreal, Quebec H3G 1Y6, Canada. The location of the laboratory where the work was performed determines which Chief Editor handles the manuscript for both paper and online submission.
2. If submission on-line is not possible Rapid Communications that do not contain complex figures may be submitted by facsimile or email to the Eastern Hemisphere Office (Fax Number: +44-113-233-3157; email: bmbnnn@bmb.leeds.ac.uk) or to the Western Hemisphere Office (Fax Number: +1-514-398-5340; email: mkrivoka@pharma.mcgill.ca). The original plus three copies should also be sent as hard copies. If submitting online, please select the Chief Editor who should handle your manuscript based on where the laboratory work was performed.
3. Reviews should be submitted on-line or, failing that, in quadruplicate to Prof. P. M. Beart, Department of Pharmacology, Monash University, Clayton, Melbourne, VIC 3168, Australia. Mini-Reviews should be submitted in quadruplicate to Professor M. Hamon, INSERM U288, Neuropsychopharmacologie Moléculaire, Cellulaire et Fonctionnelle, Facult?de Médecine Piti?Salpêtrière, 91 Boulevard de lHôpital, 75634 Paris Cedex 13, France. If submitting online, please direct your Review or Mini-Review to Professor A. J. Turner.
4. Hard copies of manuscripts are not returned to authors following the final decision. The originals of figures will only be returned if requested in advance.
5. Items for the Calendar of Events and Announcement sections are only available on the ISN Portal. Contributions and any queries regarding these should be sent to Dr D. Shine. Do not submit items for Calendar of Events and Announcement sections online.
6. Matters Arising. Contributions for Matters Arising are also on the ISN Portal. The article that stimulated comment should have appeared in the Journal; submission should be within six months of publication of the article in question. Interested or affected parties will be offered the right to reply in the same issue of the Journal. Submission and reply should be restricted to one printed page each. Do not submit Matters Arising online. Contributions and any further queries regarding this should be sent to Dr D. Shine.
III. MANUSCRIPT REQUIREMENTS
1. Lay-out of Original Articles
(a) Normally, manuscripts that are judged to be longer than ten printed pages will not be considered, and will be returned to the authors for shortening without review. Ten printed pages is approximately equivalent to 33 double-spaced typewritten pages (10 000 words), which must be reduced proportionately to allow for the Figures and Tables. Most graphs occupy about one-fourth of a page, whereas halftone plates may occupy one-half to a full page. Concise well-written papers are generally processed more quickly than long ones.
(b) Manuscripts should be typewritten with double spacing throughout and with margins at least 2.5 cm wide. They should be submitted in quintuplicate and on disk if not submitted online.
(c) Each manuscript must have a title page that includes only the title, authors names, laboratory of origin, name, address, telephone and telefax numbers, and must include the email address of the person to whom proofs and reprint requests should be addressed, and any necessary footnotes, including one defining abbreviations used in the text (see 8c). Indicate specific affiliations of each author. Information concerning sources of financial support should be placed in an Acknowledgment section, between Discussion and References.
(d) The page following the title page should include a brief abstract (see 5a), up to six keywords, and a running title not exceeding 45 characters in length.
(e) Papers should not be numbered in series, but subtitles are acceptable.
(f) Pages should be numbered in succession, the title page being page 1.
(g) Each table should be on a separate page at the end of the manuscript, followed by a page of figure legends, typewritten with double spacing. The approximate location of figures and tables should be indicated in the margin of the text.
(h) Footnotes to the text should be used sparingly, should be indicated by superscript numbers, and typed with corresponding numbers on a separate sheet. In Tables, reference to footnotes should be made with superscript lowercase letters.
(i) Greek characters should be clearly indicated. Identify in the margin ambiguous characters such as 1 (one or el), 0 (zero or oh), and, when handwritten, such letters as C, P and K (upper or lower case).
(j) Simple chemical compounds should be named in the text of the Experimental and Results sections by formulae when these can be printed in single horizontal lines of type.
(k) Isotopic specifications should conform to the IUPAC system Biochem. J. (1978) 169, 1-27. Full details of specific activities of isotopes used, with corrections and efficiency of counting, should be given. Results should be expressed in absolute terms, e.g. Ci, dps and dpm.
(l) Drug names should be the official or approved names; trade names or common names may be given in brackets where the drug is first mentioned.
(m) The IUB Enzyme Commission (EC) number must be quoted with the full name of the enzyme when it is first mentioned in the text. Subsequently the accepted trivial name shall be used, e.g. full name: Acetyl-CoA, choline O-acetyltransferase (EC 2.3.1.6), trivial name: choline acetyltransferase not choline acetylase. For this information the author should refer to Enzyme Nomenclature (1992), Academic Press, San Diego and London. (Units of enzyme activity should be defined in terms of the rate of the reaction catalyzed under specified conditions.) The official Système Internationale (SI) unit is the katal, i.e. mol of substrate transformed (or product formed)/s. However, it may be expressed in other terms, provided clear definitions are given, e.g. µmol/s or µmol/min.
(n) Solutions. Although SI recommends concentrations to be expressed as mol/L rather than M and that % (wt/vol) and % (vol/vol) should be given as g/L and mL/L, respectively, the use of M, % (wt/vol), and % (vol/vol) will be allowed. N is not permitted. Fractional concentrations should be expressed in decimal form.
(o) Centrifugation conditions should be expressed in terms of g and time; not in revolutions per minute.
2. Form for Rapid Communications
(a) Rapid Communications cannot exceed four printed pages in the Journal inclusive of all figures and tables. This is equivalent to 24 000 characters (one space is one character, as is one letter). Headings and each table and figure within a manuscript decrease the space available for text; an accurate estimate of the character equivalence of tables and figures can be made by looking at any issue of the Journal and this must be considered when preparing your manuscript. As a guide, please deduct 1500, 2000 and 3000 characters from the total character count of the text for each single, two-thirds or double-column figure/table to be included in the article, respectively. The character count is the definitive parameter - the size, spacing and style of type that authors use to prepare the manuscript are not relevant.
(b) Manuscripts should be submitted in quadruplicate. The number of characters must be given. A covering letter that explains why the paper warrants particularly rapid publication should be included.
(c) The manuscript should include an Abstract, and Materials and methods, Results and Discussion sections. The results and discussion may be combined, if appropriate.
(d) Manuscripts that are either obviously too long or do not follow the above instructions, will be returned to the author(s) without review.
3. Form for Reviews and Mini-Reviews
Reviews should not occupy more than 14 printed pages of the journal and should be authoritative and topical accounts of the subject area, which must be of direct relevance to a neurochemical audience. Mini-Reviews should not occupy more than four printed pages of the journal (as for Rapid Communications). They should take the form of a viewpoint, commentary or opinion on a topic of considerable contemporary interest and should appeal to the broad discipline of neurochemistry. Mini-Reviews on emerging neurochemical areas are also welcome. Mini-Reviews will be handled in the same manner as Rapid Communications ensuring a rapid decision and publication time.
4. Style
(a) Manuscripts should be concisely written in a readily understandable style. Technical neologisms, laboratory slang or words not defined in dictionaries should not be used.
(b) Redundant words, phrases and sentences should not be used. The captions of Tables and Figures, with or without paraphrasing, should not be repeated in the text. The Editors reserve the right to revise the wording of manuscripts accepted for publication in the Journal.
Authors should familiarize themselves with the double-column format and style of recently published papers.
5. Organization
(a) Each paper must begin with a brief Abstract. It should not exceed 200 words. Only the abbreviations allowed without definition (see 8b) may be used in the abstract.
(b) An introductory statement should give the reasons for undertaking the investigation and a summary of the experimental plan. Exhaustive reviews of the literature should be avoided.
(c) Experimental procedures or Materials and methods. Special chemicals etc. with their sources should be grouped under a separate subheading Materials. Procedures should be given in sufficient detail to permit the repetition of the work by others. Published procedures should be summarized, but not described in detail unless they have been substantially modified. If the procedures used are described in detail in articles that are in press, copies of such unpublished articles must accompany the submitted manuscript.
(d) Results. The findings should be described without discussion of their significance. Experimental conclusions should normally be based on an adequate number of observations with statistical analysis of variance and the significance of differences. (See 6f.)
(e) Discussion. The significance of the findings should be assessed in relation to the status of the field.
6. Presentation of Data in Tables or Figures
(a) Tables and Figures should be constructed so that they, together with their captions and legends, will be intelligible with minimal reference to the text. Use the table function of a word processor rather than tabs and spaces. For postal submission, type each table, double-spaced on a separate page.
Supplementary material such as video clips can be made available in the online Journal, and can be submitted online with RTF manuscripts (complete instructions can be found in the author center of the journals Manuscript Central site).
(b) Only in exceptional cases may the same data be published in a Table and a Figure.
(c) Each Figure must be accompanied by an explanatory legend, typewritten with double spacing. Do not use a separate sheet for each legend. Explain all symbols used in the Figure. For online submission, follow the instructions for submitting figures with RTF manuscripts. Figure legends should be included in the manuscript text, and tags inserted to indicate where each figure is to be placed. Figures can be embedded for upload as PDF or Postscript.
(d) Each column of a Table should carry an appropriate heading.
(e) The units of measurement must be indicated clearly in the column headings of a Table or the coordinates of a Figure. If the unit of measurement is the same for all the data in a Table, it may be given in the caption or in a line to be printed immediately below the Table.
(f) Data should be presented as clearly defined mean values with some measure of their dispersion (e.g. standard deviation or standard error, and range) and an indication, with appropriate symbols, of the statistical significance of differences from control values (e.g. *p p p (g) Each Figure must have its number, the authors names and J. Neurochem. written on its back. If the figures are being submitted online, it is imperative that the figure number is provided in the figure file and on the screen. Line drawings should be in camera-ready form. The Publisher guarantees to reproduce electron micrographs to the satisfaction of the author. Special attention for halftones should be requested in writing. An overlay should be provided showing which area of the halftone requires greatest definition. Halftone photographs should be submitted in the form of original photographic prints. Figures should normally be about twice the final size; in no case should the dimensions exceed 20 x 30 cm. All lettering should be of high standard and large enough to be legible when reduced to single-column size.
It is the policy of J. Neurochem. for authors to pay the full cost for the reproduction of their colour artwork. Therefore, please note that if there is colour artwork in your manuscript when it is accepted for publication, Blackwell Publishing require you to complete and return a Colour Work Agreement form before your paper can be published (click on the link to downloaded the form as a PDF* from the internet). Any article received by Blackwell Publishing with colour work will not be published until the form has been returned.
* To read PDF files, you must have Acrobat Reader installed on your computer. If you do not have this program, this is available as a free download from the following web address: http://www.adobe.com/products/acrobat/readstep2.html
(h) Symbols on graphs etc. should be inserted by the author using standard characters.
(i) Data may be presented in bar graphs where appropriate. However, three-dimensional presentation is acceptable only for data with three variants.
(j) Figures must be planned so as to avoid wasted white space. It is not necessary for the scale on a coordinate to start at 0.
(k) Authors are requested to use scale bars on micrographs.
7. References
(a) In the text, cite references by names of authors and year of publication; for papers written by three or more authors, use et al. At the end of the paper, references, typewritten with double spacing, should be listed in alphabetical order, except for papers by three or more authors, which should be grouped in chronological order after any other papers by the first author. First and last page numbers, full titles of papers, and names of all co-authors must be given.
Examples
Journal article:
Fassbender K., Simons M., Bergmann C., Stroick M., Lütjohann D., Keller P., Runz H., Kühl S., Bertsch T., Von Bergmann K., Nennerici M., Beyreuther K. and Hartmann T. (2001) Simvastin strongly reduces levels of Alzheimers disease ?amyloid peptides A?2 and A?0 in vitro and in vivo. Proc. Natl Acad. Sci. USA 98, 5856-5861.
Chapter in book:
Feenstra M. G. P. (2000) Dopamine and noradrenaline release in the prefrontal cortex in relation to unconditioned and conditioned stress and reward, in Progress in Brain Research, (Uylings H. B. M., Van Eden C. G., De Bruin J. P. C., Feenstra M. G. P. and Pennartz C. M. A., eds), Vol. 126, pp. 133-163. Elsevier Science B. V., Amsterdam.
Book:
Paxinos G. and Watson C. (1982) The Rat Brain in Stereotaxic Coordinates. Academic Press, San Diego.
Book in series:
Di Chiara G. and Gessa G. L., eds (1981) Advances in Biochemical Psychopharmacology, Vol. 27: Glutamate as a Neurotransmitter. Raven Press, New York.
Journal titles should be abbreviated in accordance with the List of Journals Indexed in Index Medicus (Superintendent of Documents, US Government Printing Office, Washington, DC 20402, USA, DHEW Publication No. 95-267).
Acta Neurol. Scand.
Acta Physiol. Scand.
Anal. Biochem.
Arch. Biochem. Biophys.
Biochem. J.
Biochem. Pharmacol.
Biochim. Biophys. Acta
Biol. Chem. Hoppe Seyler
Br. J. Pharmacol.
Eur. J. Pharmacol.
Experientia
J. Biol. Chem.
J. Cell Biol.
J. Mol. Biol.
J. Pharmacol. Exp. Ther.
J. Physiol. (Lond.)
Mol. Pharmacol.
Nature
Proc. Natl Acad. Sci. USA
Proc. Soc. Exp. Biol. Med.
Science
(b) Unpublished experiments, papers in preparation, etc., may be mentioned only in the text; they must not be included in the list of References.
(c) A paper that has been accepted for publication may be cited in the References with the abbreviated name of the Journal followed by the words, in press. The date of acceptance of each such paper should be indicated when the manuscript is submitted to the Journal of Neurochemistry. References to unpublished papers (e.g., either in press or submitted) must be accompanied by two copies of the paper for the use of referees.
(d) Personal communications may be used only when written authorization from the communicator is submitted with the original manuscript; they may be mentioned only in the text, giving name of communicator.
8. Abbreviations and Symbols
(a) The use of abbreviations should be restricted to the Système Internationale (SI) units, see Biochem. J. (1978) 169, 1-27, and a minimum of other generally accepted terms [see (b)]. Excessive use of abbreviations in the text is discouraged.
(b) The following abbreviations may be used without definition.
ADP, CDP, GDP, IDP, UDP, 5(pyro)-diphosphates of adenosine, cytidine, guanosine, inosine, and uridine AMP, etc.-5-phosphates of adenosine, etc.
ANOVA, analysis of variance
ATP, etc.-5`(pyro)-triphosphates of adenosine, etc.
ATPase, adenosine triphosphatase
bp, base pair
Ci, curie
CoA and acyl-CoA-coenzyme A and its acyl derivatives (e.g., acetyl-CoA)
cpm, counts per minute
CNS, central nervous system
CSF, cerebrospinal fluid
Cyclic AMP, 3,5-cyclic adenosine monophosphate
Cyclic GMP-3,5-cyclic guanosine monophosphate
DNA, deoxyribonucleic acid
DNase, deoxyribonuclease
DOPA, 3,4-dihydroxyphenylalanine
dpm, dps-disintegrations per minute, disintegrations per second
EDTA, ethylene-diaminetetraacetate
EEG, electroencephalogram
EGTA, ethyleneglycol bis(aminoethylether)tetraacetate
ELISA, enzyme-linked immunosorbent assay
FAD, FADH2, flavin-adenine dinucleotide and its reduced form
FMN, flavin mononucleotide
g, average gravity
GABA, gamma-aminobutyric acid (not Gaba)
GLC, gas-liquid chromatography
GSSG, GSH, glutathione, oxidized and reduced forms
h, hour
HEPES, N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid
HPLC, high performance liquid chromatography
Ig, immunoglobulin
IR, infrared
kb, kilobase
kDa, kilodalton
µm, micron
min, minute
MPP+, 1-methyl-4-phenylpyridinium
MPTP, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
NAD+, NADH-oxidized and reduced forms of nicotin-amide-adenine
dinucleotide
NADP+, NADPH-oxidized and reduced forms of nicotin-amide-adenine
dinucleotide phosphate
NAD, NADP may be used when the oxidation state need not be indicated
NMDA, N-methyl-D-aspartate
NMN, nicotinamide mononucleotide
NMR, nuclear magnetic resonance
PCR, polymerase chain reaction
Pi, orthophosphate (inorganic)
PNS, peripheral nervous system
PPi, pyrophosphate (inorganic)
rpm, revolutions per minute
RNA, ribonucleic acid
RNase, ribonuclease
RT, reverse transcription
s, second
SEM, standard error of mean
SD, standard deviation
TLC, thin-layer chromatography
Tris, 2-amino-2-hydroxymethylpropane-1,3-diol
UV, ultraviolet
(c) Other abbreviations may be used sparingly and defined in a footnote on the title page, as well as at their first mention in text. Recommended forms of abbreviation to be used with definition are as follows.
ACh, acetylcholine
AChE, acetylcholinesterase
AMPA, alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate
ChAT, choline acetyltransferase
COMT, catechol-O-methyltransferase
DA, 3,4-dihydroxyphenylethylamine or dopamine
5-HT, 5-hydroxytryptamine or serotonin
MAO, monoamine oxidase
NA, noradrenaline, norepinephrine
NeuNAc, N-acetylneuraminic acid (not NANA)
(d) Abbreviations should not be used in titles and running titles.
9. Nomenclature
As far as possible, authors should follow the recommendations of the IUPAC-IUB Joint Commission on Biochemical Nomenclature. For references to these rules see Biochemical Nomenclature and Related Documents 2nd edit. (1992), available from Portland Press Ltd., 59 Portland Place, London W1N 3AJ, UK or Portland Press Inc., PO Box 2191, Chapel Hill, NC 27515-2191, USA.
10. Protein Sequences
Protein sequences, which have been determined by direct sequencing of the protein, must be submitted to SWISS-PROT at the EMBL Outstation - The European Bioinformatics Institute. Please note that we do not provide accession numbers, IN ADVANCE, for protein sequences that are the result of translation of nucleic acid sequences. These translations will automatically be forwarded to us from the EMBL nucleotide database and are assigned SWISS-PROT accession numbers on incorporation into TrEMBL.
Results from characterization experiments should also be submitted to SWISS-PROT at the EBI. This can include such information as function, subcellular location, subunit etc.
Contact information:
SWISS-PROT Submissions, European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SD, UK.
Tel: +44 (0)1223 494400;
Fax: +44 (0)1223 494472.
Email: datasubs@ebi.ac.uk (for sequence admissions)
update@ebi.ac.ul (for characterization information)
Website: www.ebi.ac.uk
11. Revision
Review of revised papers by editors and referees will be facilitated if a summary of the changes is supplied in a letter with specific reference to the comments of editors and referees. A copy of the revised manuscript should be provided which clearly shows changes made by providing details of said changes in the margin and/or by underlining them.
When submitting a REVISED manuscript online, a form is provided with boxes for comments to the Editor and for referees. These comments MUST be submitted BEFORE the revised manuscript is uploaded (instructions are provided on the online submission site http://jneurochem.manuscriptcentral.com
For final submission online of accepted manuscripts, or as hard copies, the corresponding author is required to submit the text of accepted manuscripts on computer disk and as hard copy. When preparing the disk for submitting manuscripts electronically the following guidelines should be followed as closely as possible:
- Final version of the hard copy and the floppy disk must be the same
- It is essential that the disk contains any last-minute changes
- File name(s) should be given with the disk, with separate file names for: text, references, tables, figure captions
- If possible, electronic or files saved on disc should be supplied in both word processor and ASCII (.rtf) formats
- Be consistent. Use the same presentation for all headings, etc. that are to appear the same in the finished printing
- Advise us about any matter that you think could cause a problem
- Do not use the carriage return (enter) at the end of lines within a paragraph
- Disks will not be returned to authors
Please note that the disk version must be the version of the manuscript that was accepted for publication.
Original drawings of photographs should be supplied for reproduction. Figures will be reduced to single column width (78 mm), two-thirds page width (112 mm) or full page width (167 mm) and should be planned accordingly.
Photographs should be provided as glossy prints. Journal of Neurochemistry welcomes the publication of colour figures. Ordinarily, the cost of publishing such plates must be borne by the authors. Colour figures in Reviews and Mini-Reviews are free of charge to the authors.
Authors are required to complete a Colour Work Agreement form which will be supplied with the letter of decision requesting revision. This form should be returned to the Editor along with the revised manuscript.
We would also like to receive your artwork in electronic form. Please save vector graphics (e.g. line artwork) in Encapsulated Postscript Format (EPS), and bitmap files (e.g. halftones) in Tagged Image File Format (TIFF). Ideally vector graphics that have been saved in metafile (.WMF) or pict (.PCT) format should be embedded within the body of the text file. Click here for detailed information on our digital illustration standards. Always enclose a good quality hard copy of digitally supplied figures.
12. Proofs
Proofs will be sent to the author submitting the paper and must be returned promptly. This will allow correction of typesetters and similar errors. Major changes will not be entertained and authors may be charged for excessive amendments at this stage. Proofs will be sent via e-mail as an Acrobat PDF (portable document format) file. Therefore, the corresponding author should supply their email address when they submit their manuscript. The e-mail server must be able to accept attachments up to 4 MB in size. Acrobat Reader will be required in order to read this file. This software can be downloaded (free of charge) from the following Web site:
http://www.adobe.com/prodindex/acrobat/main.html
This will enable the file to be opened, read on screen, and printed out in order for any corrections to be added. Further instructions will be sent with the proof. Proofs will be posted if no e-mail address is available; in your absence, please arrange for a colleague to access your e-mail to retrieve the proofs.
To assure prompt publication, proofs should be mailed back to the Publisher not more than 3 working days after receipt. [To expedite the publication of Rapid Communications, authors should email the Production Editors or inform them by telefax (+44-131-226-3803) of any proof corrections; publication cannot be delayed for the return of corrected proofs by mail.] Corrections should be restricted to typesetters errors and completion of in press references.
Substantial alterations to proofs may delay publication and also be charged to authors.
13. Offprints
Offprints of each paper can be obtained at reasonable cost by using the offprint form supplied with the proofs. Fifty free offprints will be sent to the corresponding author.
14. Copyright
Copyright on articles published in the Journal of Neurochemistry will be held by the International Society for Neurochemistry, Ltd. In view of the present US copyright law, effective January 1, 1978, it is necessary that a statement be signed by the author(s) of a submitted manuscript, expressly transferring copyright to the Society in the event that the paper is published in the Journal. A Copyright Assignment Form will be sent to the corresponding author along with the letter of decision. Authors may also download and print off this form from the link provided above. One signed original of this form must be returned to the Editorial Office that is handling the manuscript along with the revised manuscript.
15. Inquiries concerning papers in press
Once authors have been informed that manuscripts have been accepted for publication, all inquiries concerning the status of manuscripts should be directed to: Production Editors, Journal of Neurochemistry, Blackwell Science Ltd, 23 Ainslie Place, Edinburgh EH3 6AJ (email: jnc@oxon.blackwellpublishing.com)
Editorial Board
Chief Editors
Brian Collier
Room 1316, Department of Pharmacology and Therapeutics, McGill University, McIntyre Medical Sciences Building, 3655 Promenade Sir-William-Osler, Montreal, Quebec H3G 1Y6, Canada
Tel: +514 398 6833
Fax: +514 398 5340
email: bcollier@pharma.mcgill.ca
Militsa Krivokapich (Editorial Coordinator)
Room 1316, Department of Pharmacology and Therapeutics, McGill University, McIntyre Medical Sciences Building, 3655 Promenade Sir-William-Osler, Montreal, Quebec H3G 1Y6, Canada
Tel: +514 398 6833
Fax: +514 398 5340
email: mkrivoka@pharma.mcgill.ca
Anthony J Turner
School of Biochemistry and Molecular Biology, University of Leeds, Leeds LS2 9JT, UK
Tel: +44 113 233 2987
Fax: +44 113 233 3157
email: a.j.turner@leeds.ac.uk
Natalia N Nalivaeva (Editorial Coordinator)
School of Biochemistry and Molecular Biology, University of Leeds, Leeds LS2 9JT, UK
Tel: +44 113 233 2987
Fax: +44 113 233 3157
email: n.n.nalivaeva@leeds.ac.uk
Editorial Board
Deputy Chief Editors
F. Checler
Institut de Pharmacologie Moléculaire et Cellulaire, CNRS, Universit?de Nice, Sophia-Antipolis, 06560 Valbonne, France
S. K. Fisher
Neuroscience Laboratory, University of Michigan, 1103 East Huron Avenue, Ann Arbor, MI 48104-1687, USA
T. Haga
Institute for Biomolecular Science, Gakushuin University, 1-5-1 Mejiro, Toshima-ku, Tokyo 171-8588, Japan
M. P. Mattson
Laboratory of Neurosciences, National Institute on Aging, 5600 Nathan Shock Drive, Baltimore, MD 21224, USA
S. Murphy
Institute of Cell Signalling, Medical School, QMC, University of Nottingham, Nottingham NG7 2UH, UK
R. J. Wenthold
NIDCD/NIH, Bldg. 50, Room 4140, Bethesda, MD 20892-4162
Deputy Chief Editor - Reviews
P. M. Beart
Department of Pharmacology, Monash University, Clayton, Melbourne, VIC 3168, Australia
M. Hamon
INSERM U288, Neuropsychopharmacologie Moléculaire, Cellulaire et Fonctionnelle, Facult?de Médecine Piti?Salpêtrière, 91 Boulevard de l'Hôpital, 75634 Paris Cedex 13, France
Editorial Board
V. Adam-Vizi (Budapest)
J. M. Arrang (Paris)
N. Avrova (St Petersburg)
G. Bagetta (Arcavacata di Rende)
J. M. Baraban (Baltimore)
M. F. Beal (New York)
J. A. Benjamins (Detroit)
H. Betz (Frankfurt)
N. R. Bhat (Charleston)
G. E. Blair (Leeds)
H. Bönisch (Bonn)
D. R. Brown (Bath)
P. J. Conn (Nashville)
B. M. Cox (Bethesda)
A. L. de Blas (Storrs)
D. Dobrota (Martin)
R. V. Dorman (Kent)
R. S. Duman (New Haven)
D. L. Feinstein (Chicago)
J. P. M. Finberg (Haifa)
A. Frandsen (Copenhagen)
P. Fredman (Mölndal)
J. Garthwaite (London)
J. D. Geiger (North Dakota)
G. E. Gibson (White Plains)
E. D. Gundelfinger (Magdeburg)
A. L. Gundlach (Melbourne)
B. Halliwell (Singapore)
R. A. Harris (Austin)
L. B. Hersh (Lexington)
S. J. Hewett (Farmington)
H. Higashida (Kanazawa)
B. J. Hoffman (Indianapolis)
Y. Ihara (Tokyo)
P. M. Iuvone (Atlanta)
P. Jenner (London)
G. V. W. Johnson (Birmingham)
F. B. Jungalwala (Waltham)
L.-S. Kao (Taipei)
R. F. Keep (Ann Arbor)
H. Kiyama (Osaka)
D. M. Kuhn (Detroit)
M. Leist (Valby)
R. K. H. Liem (New York)
C. Llorens-Cortes (Paris)
A. Machado (Seville)
W. B. Macklin (Cleveland)
R. A. J. McIlhinney (Oxford)
J. E. Merrill (Bridgewater)
N. Miki (Osaka)
M. Mishina (Tokyo)
B. Moghaddam (Pittsburgh)
E. Molnar (Bristol)
D. T. Monaghan (Omaha)
F. Moroni (Firenze)
K. A. Nalecz (Warszawa)
J.-N. Octave (Brussels)
P. Panula (Turku)
A. Pazos (Santander)
C. J. Pike (Los Angeles)
J. Pocock (London)
T. Pozzan (Padova)
M. A. M. Prado (Belo Horizonte)
S. E. Przedborski (New York)
M. Quik (Sunnyvale)
M. Raiteri (Genova)
M. Rattray (London)
I. J. Reynolds (Pittsburgh)
R. Riopelle (Montreal)
B. L. Roth (Cleveland)
N. Saito (Kobe)
J. Sanchez-Prieto (Madrid)
R. M. Sapolsky (Stanford)
G. Schettini (Genova)
G. Schiavo (London)
H. M. Schipper (Montreal)
A. Schousboe (Copenhagen)
H. Schulman (Stanford)
J. B. Schulz (Tübingen)
A. Sebastião (Lisbon)
F. R. Sharp (Cincinnati)
D. R. Sibley (Bethesda)
D. Small (Melbourne)
A. I. Smith (Melbourne)
M. A. Smith (Cleveland)
S. Sonnino (Milan)
P. K. Sonsalla (Piscataway)
J. E. Springer (Lexington)
P. G. Strange (Reading)
Y.-H. Suh (Seoul)
J. G. Sutcliffe (La Jolla)
R. A. Swanson (San Francisco)
M. Teitler (Albany)
M. Weller (Tübingen)
B. H. C. Westerink (Groningen)
S. R. Whittemore (Louisville)
H. Wiesinger (Tübingen)
R. J. Williams (London)
S. R. Williams (Manchester)
M. E. Wolf (North Chicago)
T. M. Wong (Hong Kong)
S. Wonnacott (Bath)
B. Zalc (Paris)
H. Zimmermann (Frankfurt)
Advisory Board - Reviews
R. Cappai (Melbourne)
E. Hirsch (Paris)
M. McKenna (Baltimore)
M. Stachowiak (Buffalo)
B. Yamamoto (Boston)
International Society for Neurochemistry Publications Committee
J. B. Clark (London) (Chairman)
R. Butterworth, Ex Officio (Montreal)
B. Collier, Ex-Officio (Montreal)
S.K. Fischer (Ann Arbor)
A. Garcia, Ex Officio (Barcelona)
M. Hamon (Paris)
S. Murphy (Nottingham)
I. J. Reynolds (Pittsburg)
A. Schousboe , Ex-Officio (Copenhagen)
H. D. Shine (Houston)
H. Soreq (Jerusalem)
A. J. Turner, Ex-Officio (Leeds)
| 
